In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast.
Pazopanib is taken fasted in a fixed oral daily dose of 800mg. We hypothesized that ingesting pazopanib with food may improve patients' comfort and reduce gastro-intestinal adverse events. Therefore we investigated the bio-equivalent dose of pazopanib when taken with food compared to 800mg pazopanib taken fasted. In addition we investigated the differences in GI-toxicity, patient satisfaction and patient's preference for either intake. The intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast.Publication
The effect of using pazopanib with food vs fasted on pharmacokinetics, patient safety and preference (DIET study).
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.
Floor Lubberman is member of theme Urological cancers.